


I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Date: August 31, 2007

By:   
Kay L. Gaviglio



PATENT  
Docket No. GC821-2-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	)	Confirmation No. 6954
Amin et al.	)	
	)	Group Art Unit: Unassigned
Serial No.: 10/581,014	)	
	)	Examiner: Unassigned
Filed: May 30, 2006	)	
	)	
For: PERHYDROLASE	)	

Information Disclosure Statement

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449 and attached thereto) of which they are aware, that they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

- (a) ☐ accompanies the new patent application submitted herewith. 37 CFR §1.97(a).
- (b) ☐ is filed within three months after the filing date of the application or within three months after the date of entry into the national stage of a PCT application as set forth in 37 CFR §1.491.
- (c) ☒ as far as is known to the undersigned, is filed before the mailing date of a first Office Action on the merits.
- (d) ☐ is filed after the first Office Action and more than three months after the application filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final

rejection or a notice of allowance, whichever occurs first, and is accompanied by either the fee (\$180.00) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR §1.97(e), as checked below. Authorization to charge Deposit Account No. 07-1048 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement is provided in the Transmittal Letter submitted herewith in duplicate.

(e) ☐ is filed after the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by authorization (in the Transmittal Letter submitted herewith in duplicate) to charge Deposit Account No. 07-1048 the fee (\$180.00) set forth in 37 CFR §1.17(l)(1) and a certification as specified in 37 CFR §1.97(e), as checked below. **This document is to be considered as a petition requesting consideration of the Supplemental Information Disclosure Statement.**

**[If either of boxes (d) or (e) is checked above, the following "certification" under 37 CFR §1.97(e) may need to be completed.]** The undersigned certifies that:

☐ Each item of information contained in the Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

☐ No item of information contained in this Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s)

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.


The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,


Dated: August 31, 2007

  
\_\_\_\_\_  
Jill A. Jacobson  
Registration No.: 40,030

Genencor Division of Danisco US Inc.  
925 Page Mill Road  
Palo Alto, CA 94304-1013  
Tel: 650-846-4072  
Fax: 650-845-6504

**INFORMATION DISCLOSURE CITATION**

<b>Attorney Docket No.:</b> GC821-2-US	<b>Serial No.:</b> 10/581,014
<b>Applicant:</b> Amin et al.	
<b>Filing Date:</b> May 30, 2006	<b>Group:</b> Unassigned
<b>Page</b> <u>1</u> <b>of</b> <u>3</u>	<b>Date of this Submission:</b> August 31, 2007



**US PATENT DOCUMENTS**

Examiner's Initial	Document Number	Date	Name	Class	Sub-Class	Filing Date
	2002-0007516	01/24/02	Wang			
	2003-0191033	10/09/03	Ryu et al.			
	2007-0105740	05/10/07	Dicosimo et al.			
	3,823,070	07/09/74	Minato et al.			
	3,974,082	08/10/76	Weyn			
	4,008,125	02/15/77	Kurozumi et al.			
	4,261,868	04/14/81	Hora et al.			
	4,400,237	08/234/83	Kruger et al.			
	4,404,128	09/13/83	Anderson			
	4,415,657	11/15/83	Umezawa et al.			
	4,430,243	02/07/84	Bragg			
	4,594,324	06/10/86	Dalton et al.			
	4,683,195	07/28/87	Mullis et al.			
	4,683,202	06/28/87	Mullis			
	4,965,188	10/23/90	Mullis et al.			
	4,977,252	12/11/90	Chiu			
	5,030,240	07/09/91	Wiersema et al.			
	5,108,457	04/28/92	Poulouse et al.			
	5,204,015	04/20/93	Caldwell et al.			
	5,240,835	08/31/93	Pettrone et al.			
	5,254,283	10/19/93	Arnold et al.			
	5,296,616	03/22/94	Namekawa et al.			
	5,352,594	10/04/94	Poulouse			
	5,354,559	10/11/94	Morehouse			
	5,370,770	12/06/94	Johnson et al.			
	5,486,303	01/23/96	Capeci et al.			
	5,489,392	02/06/96	Capeci et al.			
	5,516,448	05/14/96	Capeci et al.			
	5,486,303	01/23/96	Capeci et al.			
	5,565,422	10/15/96	Del Greco et al.			
	5,569,645	10/29/96	Dinniwell et al.			
	5,574,005	11/12/96	Welch et al.			

<b>Examiner</b>	<b>Date Considered</b>

**Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**PTO-1449**

**INFORMATION DISCLOSURE CITATION INFORMATION DISCLOSURE CITATION**

<b>Attorney Docket No.:</b> GC821-1-US	<b>Serial No.:</b> 10/581,014
<b>Applicant:</b> Amin et al.	
<b>Filing Date:</b> May 30, 2006	<b>Group:</b> Unassigned
<b>Page</b> <u>2</u> <b>of</b> <u>3</u>	<b>Date of this Submission:</b> August 31, 2007

**US PATENT DOCUMENTS**

Examiner's Initial	Document Number	Date	Name	Class	Sub-Class	Filing Date
	5,576,282	11/19/96	Miracle et al.			
	5,595,967	01/21/97	Miracle et al.			
	5,597,936	01/28/97	Perkins et al.			
	5,601,750	02/11/97	Domke et al.			
	5,691,297	11/25/97	Nassano et al.			
	5,785,812	07/28/98	Linsten et al.			
	5,879,584	03/09/99	Bianchetti et al.			
	5,935,826	08/10/99	Blue et al.			
	5,989,526	11/23/99	Aaslyng et al.			
	6,165,318	12/26/00	Paren et al.			
	6,225,464	05/01/01	Hiler, II et al.			
	6,306,812	10/23/01	Perkins et al.			
	6,326,348	12/01/01	Vinson et al.			
	6,379,653	04/30/02	Asyng et al			
	6,569,286	05/27/03	Withenshaw et al.			

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials	Document Number	Date	Country	Class	Sub-Class	Translation Yes/No
	2 094 826A	03/02/82	GB			
	0 248 660	06/03/87	EP – Appl. No. 87-304933.9			
	0 275 509	12/18/87	EP			
	0 280 232	02/22/88	EP			
	WO 91/17235	05/03/91	PCT related to USSN. 07/642,669 ABD			
	WO 97/11151	09/13/96	PCT			
	EP 1 255 888 pub. As WO 01/64993	02/15/01	PCT			
	WO 03/002810 A1	01/09/03	PCT			
	WO 03/083125	03/28/03	PCT			

<b>Examiner</b>	<b>Date Considered</b>

**Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not**

**considered. Include copy of this form with next communication to applicant.**  
**PTO-1449**

**INFORMATION DISCLOSURE CITATION INFORMATION DISCLOSURE CITATION**

<b>Attorney Docket No.:</b> GC821-1-US	<b>Serial No.:</b> 10/581,014
<b>Applicant:</b> Amin et al.	
<b>Filing Date:</b> May 30, 2006	<b>Group:</b> Unassigned
<b>Page</b> <u>3</u> <b>of</b> <u>3</u>	<b>Date of this Submission:</b> August 31, 2007

**OTHER DOCUMENTS**

Examiner's	
Initials	Author, Title, Date, Pertinent Pages, etc.
	Altschul et al., "Basic Local Alignment Search Tool," <i>J. Mol. Biol.</i> , V. 215, 1990, pp. 403-410
	Altschul et al., "Basic Local Alignment Statistics," <i>Methods in Enzymology</i> , V. 266, pp. 460-480 (1996).
	Baldry, "The bactericidal, fungicidal and sporicidal properties of hydrogen peroxide and peracetic acid," <i>J. of Applied Bact.</i> , 1983, 54, 417-423
	Chamberlin et al., "New RNA polymerase from Escherichia coli infected with Bacteriophage T7," <i>Nature</i> , V. 228, pp.227-231, October 17, 1970
	Chang, Shing et al., "High Frequency Transformation of <i>Bacillus subtilis</i> Protoplasts by Plasmid DNA," <i>Mol. Gen. Genet.</i> , 168:111-115, 1979.
	Devereux et al., "A Comprehensive set of sequence analysis programs for the VAX," <i>Nucl. Acids Res.</i> , Vol. 12, p. 387-395, 1984.
	Feng et al., "Progressive Sequence Alignment as a Prerequisite to Correct Phylogenetic Tress" <i>J. Mol Evol.</i> Vol. 25, pp. 351-360, 1987.
	Ferrari, E. et al., "Genetics" <i>Bacillus</i> , Harwood (ed.), Plenum Publishing Corporation, pp. 57-72, 1989.
	Goffin and Ghysen, "Biochemistry and comparative genomics of SxxK superfamily acyltransferases offer a clue to the mycobacterial paradox: presence of penicillin-susceptible target proteins versus lack of efficiency of penicillin as therapeutic agent", <i>Microbiology and Molecular Biology Reviews</i> , Dec. 2002, V. 66, N. 4, pp. 702-728
	Henikoff, Steven et al., "Amino acid substitution matrices from protein blocks," <i>Proc. Natl. Acad. Sci. USA</i> , 89:10915-10919, November 1992.
	Higgins et al., "Clustal: a package for performing multiple sequence alignment on a microcomputer," <i>Gene</i> , 73 (1988) 237-244
	Higgins et al., "Fast and sensitive multiple sequence alignments on microcomputer," <i>CABIOS</i> , Vol. 5, 1989, p. 151-153.
	Hofmann et al., "Bleaching Activators and the Mechanism of Bleaching Activation," <i>J. prakt. Chem.</i> , 334 (1992) 293-297
	Hosie et al., "p-Nitrophenyl and Cholesteryl-N-Alkyl Carbamates as Inhibitors of Cholesterol Esterase", <i>J. of Biological Chemistry</i> , V. 262, N. 1, pp. 260-264, January 5, 1987
	Kacian et al., "A replicating RNA molecule suitable for a detailed analysis of extracellular evolution and replication", <i>Proc. Nat. Acad. Sci. USA</i> , V. 69, N. 10, pp3038-3042, October 1972
	Karlin et al., "Applications and statistics for multiple high-scoring segments in molecular sequences," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 90, pp. 5873-5877, June 1993
	Molgaard et al., "Rhamnogalacturonan acetyltransferase elucidates the structure and function of a new family of hydrolases," <i>Structure</i> 2000, V. 8, N. 4., pp. 373-383
	Needleman et al., "A General Method App licable to the Search for Similarities in the Amino Acid Sequence of Two Proteins," <i>J. Mol. Biol.</i> , Vol. 48, pp. 443-453, 1970
	Pearson et al., "Improved tools for biological sequence comparison," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 85, pp. 2444-2448, April 1988
	Pinkernell et al., "Selective Phtometric Deermination of Peroxycarboxylic Acids in the Presence of Hydrogen Peroxide," <i>Analyst</i> , June 1997, KV. 122 567-571
	Sakai et al., "A novel arylesterase active toward 7-Aminocephalosporanic Acid from <i>Agrobacterium radiobacter</i> IFO 12607: Nucleotide sequence, gene expression in <i>Escherichia coli</i> , and site-directed mutagenesis", <i>J. of Fermentation and Bioengineering</i> , (1998) 85:138-143
	Salazar et al., "Transcription analysis of the dnaA gene and oriC region of the chromosome of <i>Mycobacterium smegmatis</i> and <i>Mycobacterium bovis</i> BCG, and its regulation by the DnaA protein," <i>Microbiology</i> , V. 149, pp. 773-784
	Smith et al., "Comparison of Biosequences," <i>Adv. In App. Math.</i> Vol. 2, pp 482-489, 1981
	Smith, Michael et al., "Protoplast Transformation in Coryneform Bacteria and Introduction of an $\alpha$ -Amylase Gene from <i>Bacillus amyloliquefaciens</i> into <i>Brevibacterium lactofermentum</i> ," <i>Applied and Environmental Microbiology</i> , vol. 51, no. 3, pp. 634-639, March, 1986.
	Upton et al., "A New Family of Lipolytic enzymes ". <i>TIBS</i> , V. 20 – pp 178-179 May 1995
	Vagner, et al., "A vector for systematic gene inactivation in <i>Bacillus subtilis</i> ," <i>Microbiology</i> , (1998) V.144, pp. 3097-3104
	Wu et al., "The ligation amplification reaction (LAR)—amplification of specific DNA sequences using sequential rounds of template-depandent ligation", <i>Genomics</i> , V. 4, pp. 560-569 (1989)

<b>Examiner</b>	<b>Date Considered</b>
<b>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</b>	
<b>PTO-1449</b>	